<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39403696</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2666-6235</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Journal of migration and health</Title><ISOAbbreviation>J Migr Health</ISOAbbreviation></Journal><ArticleTitle>Differences in characteristics and interactions with close contacts among PWID in the San Diego Border Region before and during the COVID-19 pandemic.</ArticleTitle><Pagination><StartPage>100267</StartPage><MedlinePgn>100267</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100267</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jmh.2024.100267</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Travel restrictions implemented to mitigate the spread of SARS-CoV-2 decreased mobility and reduced physical contact during 2020-2021 for many in the general population. This analysis explored changes to network contacts among people who inject drugs (PWID) in the San Diego Border Region (SDBR) by cross-border mobility before and during the COVID-19 era.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Baseline data collected between October 2020-2021, from a cohort study of PWID in the SDBR were used to retrospectively describe differences in baseline characteristics across cross-border PWID groups (cross-border PWID [CB-PWID]: <i>n</i> = 206; San Diego PWID [SD-PWID]: <i>n</i> = 203; Tijuana PWID [TJ-PWID]: <i>n</i> = 202). Chi-square and Fisher's exact tests evaluated sociodemographic, injecting risk behaviors, harm reduction service history, incarceration history, non-fatal overdose, HCV, HIV. Median differences in sex, drug/alcohol, and close partners before and during the pandemic among all PWID and by cross-border PWID status were evaluated using Kruskal-Wallis tests. Pairwise associations across cross-border PWID groups were assessed using the Dwass, Steel, Critchlow-Fligner multiple comparison test.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Among 611 PWID, the number of sex, drug/alcohol-related partners and close contacts before and during the pandemic remained relatively stable (p<sub>sex</sub>=0.71;p<sub>drug/alcohol</sub>=0.15;p<sub>close</sub>=0.09). PWID in San Diego experienced the greatest difference in drug/alcohol-related partners (median[IQR]:-1[-6,0]), while cross-border PWID reported the smallest change in close contacts versus pre-pandemic (median[IQR]:0[0,1]). PWID in Tijuana had the greatest proportion (87%) of close contacts who injected drugs of all three groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Compared to pre-pandemic, the median number of sex partners, drug/alcohol-related partners, and close contacts remained stable among PWID in the SDBR. Future research should explore how these network contacts evolve over time.</AbstractText><CopyrightInformation>© 2024 The Authors. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marquez</LastName><ForeName>Lara K</ForeName><Initials>LK</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Global Public Health, University of California San Diego, 9500 Gilman Drive, La Jolla 92037, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Natasha K</ForeName><Initials>NK</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Global Public Health, University of California San Diego, 9500 Gilman Drive, La Jolla 92037, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strathdee</LastName><ForeName>Steffanie A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Global Public Health, University of California San Diego, 9500 Gilman Drive, La Jolla 92037, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skaathun</LastName><ForeName>Britt</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Global Public Health, University of California San Diego, 9500 Gilman Drive, La Jolla 92037, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Migr Health</MedlineTA><NlmUniqueID>101774615</NlmUniqueID><ISSNLinking>2666-6235</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 pandemic</Keyword><Keyword MajorTopicYN="N">Social networks</Keyword><Keyword MajorTopicYN="N">Substance use</Keyword></KeywordList><CoiStatement>The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Natasha Martin has received honoraria from Merck, Gilead, and AbbVie.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>10</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>4</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39403696</ArticleId><ArticleId IdType="pmc">PMC11471669</ArticleId><ArticleId IdType="doi">10.1016/j.jmh.2024.100267</ArticleId><ArticleId IdType="pii">S2666-6235(24)00056-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aponte-Melendez Y., Mateu-Gelabert P., Fong C., Eckhardt B., Kapadia S., Marks K. The impact of COVID-19 on people who inject drugs in New York City: increased risk and decreased access to services. Harm. Reduct. J. 2021;18:118. doi: 10.1186/s12954-021-00568-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12954-021-00568-3</ArticleId><ArticleId IdType="pmc">PMC8611635</ArticleId><ArticleId IdType="pubmed">34819070</ArticleId></ArticleIdList></Reference><Reference><Citation>Borquez A., Garfein R.S., Abramovitz D., Liu L., Beletsky L., Werb D., et al. Prevalence and correlates of injecting with visitors from the United States among people who inject drugs in Tijuana, Mexico. J. Immigr. Minor. Health. 2019;21:1200–1207. doi: 10.1007/s10903-019-00868-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10903-019-00868-8</ArticleId><ArticleId IdType="pmc">PMC6697237</ArticleId><ArticleId IdType="pubmed">30771144</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucardo J., Brouwer K.C., Magis-Rodriguez C., Ramos R., Fraga M., Perez S.G., et al. Historical trends in the production and consumption of illicit drugs in Mexico: implications for the prevention of blood borne infections. Drug Alcohol Depend. 2005;79:281–293. doi: 10.1016/j.drugalcdep.2005.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drugalcdep.2005.02.003</ArticleId><ArticleId IdType="pmc">PMC2196212</ArticleId><ArticleId IdType="pubmed">16102372</ArticleId></ArticleIdList></Reference><Reference><Citation>Croxford S., Emanuel E., Ibitoye A., Njoroge J., Edmundson C., Bardsley M., et al. Preliminary indications of the burden of COVID-19 among people who inject drugs in England and Northern Ireland and the impact on access to health and harm reduction services. Public Health. 2021;192:8–11. doi: 10.1016/j.puhe.2021.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.puhe.2021.01.004</ArticleId><ArticleId IdType="pmc">PMC7836733</ArticleId><ArticleId IdType="pubmed">33601307</ArticleId></ArticleIdList></Reference><Reference><Citation>Damon W., Callon C., Wiebe L., Small W., Kerr T., McNeil R. Community-based participatory research in a heavily researched inner city neighbourhood: perspectives of people who use drugs on their experiences as peer researchers. Soc. Sci. Med. 2017;176:85–92. doi: 10.1016/j.socscimed.2017.01.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.socscimed.2017.01.027</ArticleId><ArticleId IdType="pmc">PMC5438752</ArticleId><ArticleId IdType="pubmed">28135693</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleiz C., Domínguez M., Villatoro Velazquez J., Quiroz F., Mora E., Ramos R., et al. 2019. Cuqueando La Chiva: Contextos del Consumo De Heroína En La Frontera Norte De México.</Citation></Reference><Reference><Citation>Friedman S.R., Neaigus A., Jose B., Curtis R., Goldstein M., Ildefonso G., et al. Sociometric risk networks and risk for HIV infection. Am. J. Public Health. 1997;87:1289–1296. doi: 10.2105/ajph.87.8.1289.</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/ajph.87.8.1289</ArticleId><ArticleId IdType="pmc">PMC1381088</ArticleId><ArticleId IdType="pubmed">9279263</ArticleId></ArticleIdList></Reference><Reference><Citation>Government of Canada (2021). Opioid- and Stimulant-related Harms in Canada. https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants/ Accessed: January 20, 2022.</Citation></Reference><Reference><Citation>Grov C., Zohra F., Westmoreland D.A., Mirzayi C., D'Angelo A., Stief M., et al. Sex in the Era of COVID-19 in a U.S. national cohort of cisgender men, transgender women, and transgender men who have sex with men: april-May 2020. Arch. Sex. Behav. 2022;51:343–354. doi: 10.1007/s10508-021-02121-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10508-021-02121-6</ArticleId><ArticleId IdType="pmc">PMC8628839</ArticleId><ArticleId IdType="pubmed">34845579</ArticleId></ArticleIdList></Reference><Reference><Citation>Horyniak D., Wagner K.D., Armenta R.F., Cuevas-Mota J., Hendrickson E., Garfein R.S. Cross-border injection drug use and HIV and hepatitis C virus seropositivity among people who inject drugs in San Diego, California. Int. J. Drug Policy. 2017;47:9–17. doi: 10.1016/j.drugpo.2017.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drugpo.2017.06.006</ArticleId><ArticleId IdType="pmc">PMC5592143</ArticleId><ArticleId IdType="pubmed">28683432</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirst M.J. Social capital and beyond: a qualitative analysis of social contextual and structural influences on drug-use related health behaviors. J. Drug Issues. 2009;39:653–676. doi: 10.1177/002204260903900309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/002204260903900309</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarus L., Patel S., Shaw A., Leblanc S., Lalonde C., Hladio M., et al. Uptake of community-based peer administered HIV point-of-care testing: findings from the PROUD study. PLoS. One. 2016;11 doi: 10.1371/journal.pone.0166942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0166942</ArticleId><ArticleId IdType="pmc">PMC5135055</ArticleId><ArticleId IdType="pubmed">27911908</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarus L., Shaw A., LeBlanc S., Martin A., Marshall Z., Weersink K., et al. Establishing a community-based participatory research partnership among people who use drugs in Ottawa: the PROUD cohort study. Harm. Reduct. J. 2014;11:26. doi: 10.1186/1477-7517-11-26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1477-7517-11-26</ArticleId><ArticleId IdType="pmc">PMC4203893</ArticleId><ArticleId IdType="pubmed">25307356</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall C., Perreault M., Archambault L., Milton D. Experiences of peer-trainers in a take-home naloxone program: results from a qualitative study. Int. J. Drug Policy. 2017;41:19–28. doi: 10.1016/j.drugpo.2016.11.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drugpo.2016.11.015</ArticleId><ArticleId IdType="pubmed">28027483</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreland A., Herlihy C., Tynan M.A., Sunshine G., McCord R.F., Hilton C., et al. Timing of state and territorial COVID-19 stay-at-home orders and changes in population movement - United States, March 1-May 31, 2020. MMWR. Morb. Mortal. Wkly. Rep. 2020;69:1198–1203. doi: 10.15585/mmwr.mm6935a2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6935a2</ArticleId><ArticleId IdType="pmc">PMC7470456</ArticleId><ArticleId IdType="pubmed">32881851</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson L., DeBeck K., Feng C., Kerr T., Wood E. Employment and risk of injection drug use initiation among street involved youth in Canadian setting. Prev. Med. 2014;66:56–59. doi: 10.1016/j.ypmed.2014.05.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ypmed.2014.05.022</ArticleId><ArticleId IdType="pmc">PMC4125532</ArticleId><ArticleId IdType="pubmed">24989355</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons J., Singer M. I love you... and heroin: care and collusion among drug-using couples. Subst. Abuse Treat. Prev. Policy. 2006;1:7. doi: 10.1186/1747-597X-1-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1747-597X-1-7</ArticleId><ArticleId IdType="pmc">PMC1524734</ArticleId><ArticleId IdType="pubmed">16722522</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson E.H. Measurement of diversity. Nature. 1949;163:688. doi: 10.1038/163688a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/163688a0</ArticleId></ArticleIdList></Reference><Reference><Citation>Spelman T., Sacks-Davis R., Dietze P., Higgs P., Hellard M. Injection drug network characteristics as a predictor of injection behaviour. Epidemiol. Infect. 2019;147:e173. doi: 10.1017/S095026881900061X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S095026881900061X</ArticleId><ArticleId IdType="pmc">PMC6518653</ArticleId><ArticleId IdType="pubmed">31063105</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephenson J. CDC warns of surge in drug overdose deaths during COVID-19. JAMa Health Forum. 2021;2 doi: 10.1001/jamahealthforum.2021.0001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamahealthforum.2021.0001</ArticleId><ArticleId IdType="pubmed">36218421</ArticleId></ArticleIdList></Reference><Reference><Citation>Strathdee S.A., Abramovitz D., Harvey-Vera A., Vera C.F., Rangel G., Artamonova I., et al. Prevalence and correlates of SARS-CoV-2 seropositivity among people who inject drugs in the San Diego-Tijuana border region. PLoS. One. 2021;16 doi: 10.1371/journal.pone.0260286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0260286</ArticleId><ArticleId IdType="pmc">PMC8608290</ArticleId><ArticleId IdType="pubmed">34807963</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh T., Mandell W., Latkin C., Kim J. Social network characteristics and injecting HIV-risk behaviors among street injection drug users. Drug Alcohol Depend. 1997;47:137–143. doi: 10.1016/s0376-8716(97)00082-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0376-8716(97)00082-3</ArticleId><ArticleId IdType="pubmed">9298335</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Customs and Border Protection (2020). U.S. Border Patrol Southwest Border Migration https://www.cbp.gov/newsroom/stats/sw-border-migrationAccessed: November 2, 2020.</Citation></Reference><Reference><Citation>Valente T.W., Vlahov D. Selective risk taking among needle exchange participants: implications for supplemental interventions. Am. J. Public Health. 2001;91:406–411. doi: 10.2105/ajph.91.3.406.</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/ajph.91.3.406</ArticleId><ArticleId IdType="pmc">PMC1446573</ArticleId><ArticleId IdType="pubmed">11236405</ArticleId></ArticleIdList></Reference><Reference><Citation>Volkmann T., Shin S.S., Garfein R.S., Patterson T.L., Pollini R.A., Wagner K.D., et al. Border crossing to inject drugs in Mexico among injection drug users in San Diego, California. J. Immigr. Minor. Health. 2012;14:281–286. doi: 10.1007/s10903-011-9462-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10903-011-9462-9</ArticleId><ArticleId IdType="pmc">PMC3163238</ArticleId><ArticleId IdType="pubmed">21442300</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner K.D., Moynihan M.J., Strathdee S.A., Cuevas-Mota J., Clark M., Zuniga M.L., et al. The social and environmental context of cross-border drug use in Mexico: findings from a mixed methods study of young injection drug users living in San Diego, CA. J. Ethn. Subst. Abuse. 2012;11:362–378. doi: 10.1080/15332640.2012.735182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15332640.2012.735182</ArticleId><ArticleId IdType="pmc">PMC3531810</ArticleId><ArticleId IdType="pubmed">23216441</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q.Q., Kaelber D.C., Xu R., Volkow N.D. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol. Psychiatry. 2021;26:30–39. doi: 10.1038/s41380-020-00880-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-020-00880-7</ArticleId><ArticleId IdType="pmc">PMC7488216</ArticleId><ArticleId IdType="pubmed">32929211</ArticleId></ArticleIdList></Reference><Reference><Citation>Weeks M.R., Clair S., Borgatti S.P., Radda K., Schensul J.J. Social networks of drug users in high-risk sites: finding the connections. AIDS Behav. 2002;6:193–206. doi: 10.1023/A:1015457400897.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1015457400897</ArticleId></ArticleIdList></Reference><Reference><Citation>Weeks M.R., Li J., Dickson-Gomez J., Convey M., Martinez M., Radda K., et al. Outcomes of a peer HIV prevention program with injection drug and crack users: the risk avoidance partnership. Subst. Use Misuse. 2009;44:253–281. doi: 10.1080/10826080802347677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10826080802347677</ArticleId><ArticleId IdType="pmc">PMC2896279</ArticleId><ArticleId IdType="pubmed">19142824</ArticleId></ArticleIdList></Reference><Reference><Citation>White E.F., Garfein R.S., Brouwer K.C., Lozada R., Ramos R., Firestone-Cruz M., et al. Prevalence of hepatitis C virus and HIV infection among injection drug users in two Mexican cities bordering the U.S. Salud. Publica Mex. 2007;49:165–172. doi: 10.1590/s0036-36342007000300001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/s0036-36342007000300001</ArticleId><ArticleId IdType="pmc">PMC2743977</ArticleId><ArticleId IdType="pubmed">17589770</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>